Precision Medicine
- 1st Edition, Volume 190 - August 23, 2022
- Editor: David B. Teplow
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 9 7 8 4 - 3
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 9 7 8 5 - 0
Precision Medicine, Volume 190 in the Progress in Molecular Biology and Translational Science series, highlights new advances in the field, with this new volume presenting in… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quotePrecision Medicine, Volume 190 in the Progress in Molecular Biology and Translational Science series, highlights new advances in the field, with this new volume presenting interesting chapters on a variety of topics, including Evolution of Biomarkers and Strategies for Integrating the Precision Philosophy to Guide Monitoring of Individualized Autoimmunity Conditions and to Implement the Philosophy into Clinical Practice, Precision Medicine in Epilepsy, The use of ASOs for personized medicine, Adult medicine, EGFR, NF-KB signal and regulatory noncoding RNAs in cancer, Precision medicine with multi-omics strategies, deep phenotyping, and predictive analysis, The Paradox of Personalized Medicine, and more.
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in the Progress in Molecular Biology and Translational Science series
- Updated release includes the latest information on the precision medicine
Academic, government and industrial sectors
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter One: Introduction of medical genomics and clinical informatics integration for p-Health care
- Abstract
- 1: Introduction
- 2: State-of-the-art advanced data integration
- 3: Case studies
- 4: Privacy and security
- 5: Conclusion
- References
- Chapter Two: Precision diagnostics in cancer: Predict, prevent, and personalize
- Abstract
- 1: Introduction
- 2: NGS-based technologies
- 3: Therapy selection
- 4: Clinical trial design
- 5: Conclusions
- References
- Chapter Three: Artificial intelligence and machine learning in precision medicine: A paradigm shift in big data analysis
- Abstract
- Highlights
- 1: Introduction
- 2: Artificial intelligence and big data: Changes in the landscape of precision healthcare and medicine
- 3: The emergence of AI in precision medicine
- 4: Synergies between artificial intelligence and precision medicine
- 5: Promises of implementing AI/ML in healthcare
- 6: The integration of nanomaterials in AI-based precision medicine
- 7: The perspective of big data analytics in precision medicine
- 8: AI and personalized medicine: A case of neurological disease
- 9: Obstacles in translating big data into healthcare
- 10: Opportunities for translating big data into healthcare
- 11: Artificial intelligence and machine learning in precision medicine: An industry perspective
- 12: Future challenges and perspectives of artificial intelligence in precision medicine
- References
- Chapter Four: Precision medicine with multi-omics strategies, deep phenotyping, and predictive analysis
- Abstract
- 1: Introduction
- 2: Multi-omics strategies & precision medicine
- 3: Deep phenotyping & precision medicine
- 4: Discussion & future recommendations
- References
- Chapter Five: Progress in molecular biology and translational science addressing the needs of nano-rare patients
- Abstract
- 1: Introduction
- 2: Parsing patient populations
- 3: Mutation focused drug discovery
- 4: Prerequisites to respond to the needs of nano-rare patients
- 5: Creating an industrialized approach to the non-profit treatment of nano-rare patients
- 6: The future
- 7: Remaining challenges
- References
- Chapter Six: Precision medicine in epilepsy
- Abstract
- 1: Introduction
- 2: Precision therapy in genetic epilepsy syndromes
- 3: Precision therapy with personalized pharmacogenomics
- 4: Precision therapy with neuromodulation
- 5: Conclusion
- References
- Chapter Seven: EGFR, NF-κB and noncoding RNAs in precision medicine
- Abstract
- 1: Part 1: Epidermal growth factor receptor (EGFR)
- 2: EGFR as a target in lung cancer treatment
- 3: Acquired resistance of EGFR TKIs
- 4: Precision medicine of EGFR in lung cancer
- 5: Part 2: Nuclear factor-κappa B signaling
- 6: NF-κB signaling pathway and its activation
- 7: Part 3: Noncoding RNAs and EGFR in precision medicine
- 8: Conclusion and future perspectives
- References
- Chapter Eight: Evolution of biomarker research in autoimmunity conditions for health professionals and clinical practice
- Abstract
- 1: Introductory
- 2: Abs with catalytic activity (catAbs or abzymes)
- 3: Progressing toward personalized and precision healthcare services and challenges in applying biomarkers for clinical autoimmunity conditions
- 4: Specific autoimmunity conditions subareas
- 5: Biomarkers in clinical practice: Biomarkers as applicable to personalized dietary protocols in autoimmune conditions
- 6: Conclusion
- References
- Index
- No. of pages: 296
- Language: English
- Edition: 1
- Volume: 190
- Published: August 23, 2022
- Imprint: Academic Press
- Hardback ISBN: 9780323997843
- eBook ISBN: 9780323997850
DT
David B. Teplow
David B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid β-protein (Alzheimer's disease) and α-synuclein (Parkinson’s disease), form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA, Dr. Teplow was a faculty member in the Department of Neurology, Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles, books and book chapters, and commentaries, in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology, He is Co-Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease.
Affiliations and expertise
Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USARead Precision Medicine on ScienceDirect